SG11202103503WA - Antibodies targeting cd137 and methods of use thereof - Google Patents

Antibodies targeting cd137 and methods of use thereof

Info

Publication number: SG11202103503WA
Authority: SG; Singapore
Prior art keywords: methods; antibodies targeting; targeting; antibodies
Prior art date: 2018-10-09

Application number

SG11202103503WA

Inventor

Tea Gunde

Matthias Brock

Christian Hess

Alexandre Simonin

Stefan Warmuth

Original Assignee

Numab Therapeutics AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-09

Filing date

2019-10-09

Publication date

2021-05-28

2018-10-09 Priority claimed from EP18199334.6A external-priority patent/EP3636320A1/en

2019-10-09 Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG

2021-05-28 Publication of SG11202103503WA publication Critical patent/SG11202103503WA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG11202103503WA 2018-10-09 2019-10-09 Antibodies targeting cd137 and methods of use thereof SG11202103503WA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP18199334.6A EP3636320A1 (en)	2018-10-09	2018-10-09	Antibodies targeting cd137 and methods of use thereof
EP19166283		2019-03-29
PCT/EP2019/077368 WO2020074584A1 (en)	2018-10-09	2019-10-09	Antibodies targeting cd137 and methods of use thereof

Publications (1)

Publication Number	Publication Date
SG11202103503WA true SG11202103503WA (en)	2021-05-28

Family

ID=68208314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202103503WA SG11202103503WA (en)	2018-10-09	2019-10-09	Antibodies targeting cd137 and methods of use thereof

Country Status (11)

Country	Link
US (1)	US12209133B2 (en)
EP (1)	EP3863717A1 (en)
JP (2)	JP7672333B2 (en)
CN (1)	CN112805068B (en)
AU (1)	AU2019358442B2 (en)
CA (1)	CA3112058A1 (en)
IL (1)	IL281767B2 (en)
MA (1)	MA53852A (en)
SG (1)	SG11202103503WA (en)
TW (1)	TWI839395B (en)
WO (1)	WO2020074584A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7682102B2 (en) *	2019-05-10	2025-05-23	リビジェンバイオファーマホールディングスリミテッド	Humanized anti-cd137 antibodies and uses thereof
EP4644417A4 (en) *	2022-12-30	2026-02-11	Abclon Inc	SPECIFICLY BINDING AFFI BODY TO CD137 AND USE OF IT

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
ATE243754T1 (en)	1987-05-21	2003-07-15	Micromet Ag	MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
EP0571613B1 (en)	1991-12-13	2003-09-17	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en)	1997-06-12	2013-05-01	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
DE19819846B4 (en)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalent antibody constructs
CN1440812A (en) *	2002-02-27	2003-09-10	上海中信国健药业有限公司	Method of strengthening immune response with CD137 conjugated excitomotor
JP2006500921A (en)	2002-07-30	2006-01-12	ブリストル−マイヤーズ　スクイブ　カンパニー	Humanized antibody against human 4-1BB
KR20140133958A (en) *	2005-10-21	2014-11-20	엘에프비 유에스에이, 인크.	Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
ES2627223T3 (en)	2007-06-26	2017-07-27	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H	Presentation of binding agents
US20110311550A1 (en) *	2008-10-24	2011-12-22	The Scripps Research Institute	Agents for hcv treatment
MX337040B (en)	2010-09-09	2016-02-09	Pfizer	4-1bb binding molecules.
EP3224275B1 (en) *	2014-11-14	2020-03-04	F.Hoffmann-La Roche Ag	Antigen binding molecules comprising a tnf family ligand trimer
IL293435B1 (en)	2015-06-15	2026-04-01	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format
KR20180096789A (en) *	2016-01-11	2018-08-29	인히브릭스, 인크.	Multivalent and multispecific 41BB-binding fusion proteins
ES2981272T3 (en) *	2016-09-23	2024-10-08	Merus Nv	Binding molecules that modulate a biological activity expressed by a cell
AU2017380981B2 (en) *	2016-12-19	2025-01-30	F. Hoffmann-La Roche Ag	Combination therapy with targeted 4-1BB (CD137) agonists
AU2018224094B2 (en) *	2017-02-24	2025-04-17	Macrogenics, Inc.	Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US12202911B2 (en) *	2017-10-10	2025-01-21	Numab Therapeutics AG	Multispecific antibody comprising CD137 binding domain and PDL1 binding domain

2019
- 2019-10-07 TW TW108136280A patent/TWI839395B/en active
- 2019-10-09 SG SG11202103503WA patent/SG11202103503WA/en unknown
- 2019-10-09 CN CN201980065887.3A patent/CN112805068B/en active Active
- 2019-10-09 AU AU2019358442A patent/AU2019358442B2/en active Active
- 2019-10-09 JP JP2021518965A patent/JP7672333B2/en active Active
- 2019-10-09 MA MA053852A patent/MA53852A/en unknown
- 2019-10-09 EP EP19786325.1A patent/EP3863717A1/en active Pending
- 2019-10-09 WO PCT/EP2019/077368 patent/WO2020074584A1/en not_active Ceased
- 2019-10-09 IL IL281767A patent/IL281767B2/en unknown
- 2019-10-09 US US17/283,128 patent/US12209133B2/en active Active
- 2019-10-09 CA CA3112058A patent/CA3112058A1/en active Pending
2024
- 2024-10-18 JP JP2024184072A patent/JP2025020172A/en active Pending

Also Published As

Publication number	Publication date
IL281767B1 (en)	2025-03-01
IL281767A (en)	2021-05-31
JP2022512628A (en)	2022-02-07
MA53852A (en)	2021-08-18
TW202035457A (en)	2020-10-01
CN112805068A (en)	2021-05-14
EP3863717A1 (en)	2021-08-18
AU2019358442A1 (en)	2021-03-25
CN112805068B (en)	2024-07-05
WO2020074584A1 (en)	2020-04-16
KR20210076907A (en)	2021-06-24
TWI839395B (en)	2024-04-21
AU2019358442B2 (en)	2025-08-14
CA3112058A1 (en)	2020-04-16
US12209133B2 (en)	2025-01-28
US20210395379A1 (en)	2021-12-23
JP2025020172A (en)	2025-02-12
JP7672333B2 (en)	2025-05-07
IL281767B2 (en)	2025-07-01

Publication	Publication Date	Title
IL273841A (en)	2020-05-31	Antibodies targeting cd137 and methods of use thereof
IL276731A (en)	2020-09-30	Anti-cd73 antibodies and methods of use thereof
IL278821A (en)	2021-01-31	Anti-sirpa antibodies and methods of use thereof
SG11202010909RA (en)	2020-12-30	Anti-msr1 antibodies and methods of use thereof
ZA202300348B (en)	2024-09-25	Anti-sortilin antibodies and methods of use thereof
IL279648A (en)	2021-03-01	Anti-sirp-beta1 antibodies and methods of use thereof
SI3601358T1 (en)	2023-10-30	Anti-trem2 antibodies and methods of use thereof
SMT202300243T1 (en)	2023-11-13	Anti-tigit antibodies and methods of use thereof
SG11202108734VA (en)	2021-09-29	Anti-trem2 antibodies and methods of use thereof
ES3064823T3 (en)	2026-04-29	Anti-ly6g6d antibodies and methods of use
SG11202108403UA (en)	2021-08-30	Anti-clec2d antibodies and methods of use thereof
IL287282A (en)	2021-12-01	Anti-mertk antibodies and their methods of use
IL289952A (en)	2022-03-01	Anti-ms4a4a antibodies and methods of use thereof
IL274221A (en)	2020-06-30	Anti-apoc3 antibodies and methods of use thereof
IL277212A (en)	2020-10-29	Anti-klk5 antibodies and methods of use
IL290741A (en)	2022-04-01	Anti-cd96 antibodies and methods of use thereof
IL280338A (en)	2021-03-01	Anti-siglec-5 antibodies and methods of use thereof
IL273578A (en)	2020-05-31	Antibodies targeting pdl1 and methods of use thereof
IL283884A (en)	2021-07-29	Anti-il-36 antibodies and methods of use thereof
IL291461A (en)	2022-05-01	Anti-alpha-synuclein antibodies and methods of use thereof
IL279227A (en)	2021-01-31	Anti-siglec-7 antibodies and methods of use thereof
IL288886A (en)	2022-02-01	Antibodies and methods of use
IL281767A (en)	2021-05-31	Antibodies targeting cd137 and methods of use thereof
HK40056395A (en)	2022-03-25	Antibodies targeting cd137 and methods of use thereof
HK40031493A (en)	2021-03-12	Antibodies targeting cd137 and methods of use thereof